NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis

Cancer Research

Volumn 74, Issue 19, 2014, Pages 5644-5655

  Thapa, Dinesh ^a   Meng, Peng ^a   Bedolla, Roble G ^a   Reddick, Robert L ^a,b   Kumar, Addanki P ^a,b,c   Ghosh, Rita ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; NQO1 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

BIOSYNTHESIS; CARCINOGENESIS; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

CARCINOGENESIS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NF-KAPPA B; P300-CBP TRANSCRIPTION FACTORS; PROSTATIC NEOPLASMS; PROTEIN BINDING; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907495424     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0562     Document Type: Article

References (49)

1. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidativestress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-85.
2. Thapa D, Ghosh R. Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 2012;83:1319-30.
3. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282:125-36.
4. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A 2002;99:3099-104.
5. Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, et al. Interaction of human NAD (P) H: quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 2003;278:10368-73.
6. Shen J, Barrios RJ, Jaiswal AK. Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res 2010;70:1006-14.
7. Patrick BA, Gong X, Jaiswal AK. Disruption of NAD (P) H: quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer. Oncogene 2011;30:1098-107.
8. Ahn KS, Sethi G, Jain AK, Jaiswal AK, Aggarwal BB. Genetic deletion of NAD (P) H: quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun. N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J Biol Chem 2006;281:19798-808.
9. Garate M, Wani AA, Li G. The NAD (P) H: quinone oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 2010;48:1601-9.
10. Siegel D, Yan C, Ross D. NAD (P) H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012;83:1033-40.
11. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD (P) H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:979-87.
12. Yuan W, Xu L, Chen W, Wang L, Fu Z, Pang D, et al. Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res Treat 2011;125:467-72.
13. Sun Z, Cui Y, Pei J, Fan Z. Association between NQO1 C609T polymorphism and prostate cancer risk. Tumour Biol. 2014 May 17. [Epub ahead of print].
14. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
15. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 2012;187:707-14.
16. Jorgenson TC, Zhong W, Oberley TD. Redox imbalance and biochemical changes in cancer. Cancer Res 2013;73:6118-23.
17. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009;16:663-73.
18. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215.
19. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010;21:41-8.
20. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283:4283-94.
21. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67:6854-62.
22. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141.
23. Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomaki K, et al., NQO1 expression correlates inversely with NFkappaB activation in human breast cancer. Breast Cancer Res Treat 2012;132:955-68.
24. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8:49-62.
25. Tergaonkar V, Perkins ND. p53 and NF-kappaB crosstalk: IKKαlpha tips the balance. Mol Cell 2007;26:158-9.
26. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003;423:655-59.
27. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. Nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003;423:659-63.
28. Huang WC, Ju TK, Hung MC, Chen CC. Phosphorylation of CBP by IKKαlpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell 2007;26:75-87.
29. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, et al. Nuclear cytokine-activated IKKαlpha controls prostate cancer metastasis by repressing Maspin. Nature 2007;446:690-4.
30. Dickinson BC, Huynh C, Chang CJ. A palette of fluorescent probes with varying emission colors for imaging hydrogen peroxide signaling in living cells. J Am Chem Soc 2010;132:5906-15.
31. Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, et al. Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 2007;13:2784-94.
32. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, et al. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 2009;15:1601-11.
33. Policastro LL, Ibanez IL, Notcovich C, Duran HA, Podhajcer OL. The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid Redox Signal 2013;19:854-95.
34. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014;6:221ra215.
35. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010;16:1414-20.
36. Maxwell PJ, Coulter J, Walker SM, McKechnie M, Neisen J, McCabe N, et al. Potentiation of inflammatory CXCL8 signalling sustains cel survival in PTEN-deficient prostate carcinoma. Eur Urol 2013;64:177-88.
37. Dinkova-Kostova AT, Talalay P. NAD (P) H: quinone acceptor oxidoreductase 1(NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010;501:116-23.
38. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010;9:336-46.
39. Wu YL, Wang D, Peng XE, Chen YL, Zheng DL, Chen WN, et al. Epigenetic silencing of NAD (P) H: quinone oxidoreductase 1 by hepatitis B virus X protein increases mitochondrial injury and cellular susceptibility to oxidative stress in hepatoma cells. Free Radic Biol Med 2013;65C: 632-44.
40. ∗2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008;40:844-53.
41. Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res 2012;72:3038-47.
42. De Nicola GM, Karreth FA, Humpton TJ, Gopinatha A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-9.
43. Martinez EE, Anderson PD, Logan M, Abdulkadir SA. Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. PLoS ONE 2012;7:e46792.
44. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009;5:1403-13.
45. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, et al. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist 2012;17:212-9.
46. Ghosh R, Schoolfield J, Yeh IT, Smith ML, Hursting SD, Chan DC, et al. Loss of NADPH quinone oxidoreductase in the prostate and enhanced serum levels of cytokine-induced neutrophil chemoattractant 2alpha in hormone-stimulated noble rats: potential role in prostatic intraepithelial neoplasia development. Transl Oncol 2009;2:65-72.
47. Cheung KL, Lee JH, Khor TO, Wu TY, Li GX, Chan J, et al. Nrf2 knockout enhances intestinal tumorigenesis in Apc (min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol Carcinog 2014;53:77-84.
48. Lin TH, Liu HH, Tsai TH, Chen CC, Hsieh TF, Lee SS, et al. CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim Biophys Acta 2013;1830:4917-27.
49. Rushworth SA, MacEwan DJ, O'Connell MA. Lipopolysaccharideinduced expression of NAD (P) H: quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J Immunol 2008;181:6730-7.